Blink Tears
Polyethylene Glycol 400
Johnson & Johnson Surgical Vision, Inc.
Human Otc Drug
NDC 29943-002Blink Tears also known as Polyethylene Glycol 400 is a human otc drug labeled by 'Johnson & Johnson Surgical Vision, Inc.'. National Drug Code (NDC) number for Blink Tears is 29943-002. This drug is available in dosage form of Solution/ Drops. The names of the active, medicinal ingredients in Blink Tears drug includes Polyethylene Glycol 400 - 2.5 mg/mL . The currest status of Blink Tears drug is Active.
Drug Information:
| Drug NDC: | 29943-002 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Blink Tears |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Polyethylene Glycol 400 |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Johnson & Johnson Surgical Vision, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution/ Drops |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | POLYETHYLENE GLYCOL 400 - 2.5 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | OPHTHALMIC
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Feb, 2008 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part349 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Johnson & Johnson Surgical Vision, Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 853238
1094102
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | B697894SGQ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 29943-002-02 | 1 BOTTLE, DROPPER in 1 CARTON (29943-002-02) / 2 mL in 1 BOTTLE, DROPPER | 01 Feb, 2008 | N/A | No |
| 29943-002-15 | 1 BOTTLE, DROPPER in 1 CARTON (29943-002-15) / 15 mL in 1 BOTTLE, DROPPER | 01 Feb, 2008 | N/A | No |
| 29943-002-30 | 1 BOTTLE, DROPPER in 1 CARTON (29943-002-30) / 30 mL in 1 BOTTLE, DROPPER | 01 Feb, 2008 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose eye lubricant
Product Elements:
Blink tears polyethylene glycol 400 polyethylene glycol 400 polyethylene glycol 400 boric acid calcium chloride magnesium chloride potassium chloride water sodium borate sodium chloride sodium chlorite hyaluronate sodium
Indications and Usage:
Uses for the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to wind or sun. may be used as a protectant against further irritation.
Warnings:
Warnings for external use only. to avoid contamination, do not touch tip of container to any surface. replace cap after using. do not use if solution changes color or becomes cloudy.
Dosage and Administration:
Directions instill 1 or 2 drops in the affected eye(s) as needed.
Stop Use:
Stop use and ask doctor if: you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.
Package Label Principal Display Panel:
Principal display panel - 15 ml bottle carton $3 savings see inside new look! same great formula blink ® tears dry eye lubricating eye drops mild-moderate long-lasting relief instantly soothes & hydrates 0.5 fl oz (15 ml) sterile principal display panel - 15 ml bottle carton
Principal display panel - 30 ml bottle carton $3 savings see inside new look! same great formula blink ® tears dry eye lubricating eye drops mild-moderate long-lasting relief instantly soothes & hydrates 1 fl oz (30 ml) sterile principal display panel - 30 ml bottle carton
Principal display panel - 2 ml bottle carton blink ® tears dry eye lubricating eye drops mild-moderate long-lasting relief instantly soothes & hydrates professional sample - not for resale 0.06 fl oz (2 ml) sterile principal display panel - 2 ml bottle carton
Further Questions:
Otc - questions section in the u.s. call 1-800-347-5005 www.yourhealthyeyes.com